ClinicalTrials.gg
CompletedNCT05366764Updated Sep 10, 2025

First-in-human Study of SAR443765 in Healthy Participants and in Asthmatic Participants

A Phase 1 interventional study of SAR443765 and Placebo in Asthma, sponsored by Sanofi. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Asthma by Sanofi — 3 open to participants now, 5 under way, 1 of them phase 3. Asthma · Sanofi.

Enrollment
31st of 31
36 · median 450
Started
2022
with 1 other
Phase 1
Only one
of the 37
Registered
28th of 37
by date

Among the 37 studies in Asthma by Sanofi, this one is the 31st largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2022, is the only one in phase 1, and was the 28th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 37 studies in Asthma by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Asthma by Sanofi, or all of them as a file.
02

Study summary

This is a 3-part, parallel group treatment, Phase 1, randomized, double-blind, placebo-controlled study to assess the safety, tolerability and pharmacokinetics after sequential single and multiple ascending doses of SAR443765 in healthy adult participants, and after a single dose of SAR443765 in participants with mild-to-moderate asthma.

Read the detailed description

The anticipated study duration per participant is up to 14 weeks

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of asthma for at least 12 months and confirmed at screening based on the Global Initiative for Asthma (GINA) 2020 Guidelines
  • Controlled asthma defined as no more than 1 canister of rescue inhaler per month over the last 3 months prior to baseline
  • Elevated FeNO level defined as ≥25 ppb
  • Participants, using as-needed SABA, ICS-naïve or with existing stable treatment (at least for 3 months prior to screening) with low to medium daily dose ICS (≤500 mcg of fluticasone propionate or comparable ICS daily dosage) potentially in combination with a LABA and/or LAMA as second controller, and/or with stable daily leukotriene receptor antagonist, leukotriene synthesis inhibitor and/or chromones
  • Prebronchodilator (FEV1) ≥60% of predicted normal
  • Reversibility of at least 12% and 200 mL in FEV1 or forced vital capacity (FVC) after administration of 4 puffs (400 mcg) of albuterol/salbutamol or levalbuterol/levosalbutamol during screening or documented history of a reversibility test that meets this criteria within 5 years prior to screening or documented positive response to methacholine challenge (a decrease in FEV1 by 20% [PC20] of \<8 mg/mL) within 5 years prior to screening visit
  • Body weight between 50.0 and 105.0 kg, inclusive, if male, and between 40.0 and 95.0 kg, inclusive, if female, between 18.0 and 32.0 kg/m2
  • Male participants are eligible to participate if they use condom during study period
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: Is a woman of non- (WONCBP) OR Is a woman of childbearing potential (WOCBP) and agrees to use a method that is highly effective
  • A WOCBP must have a negative highly sensitive pregnancy test within 36 hours before the first administration of study intervention

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Any abnormal findings in medical history, physical examination, vital signs, 12-lead .
  • Chronic lung disease, or another diagnosed pulmonary or systemic disease associated with elevated peripheral eosinophil counts.
  • History of life-threatening asthma, asthma exacerbation or use of systemic within 3 months prior to screening visit
  • Worsening of asthma or respiratory infection within the last 6 weeks prior screening visit.
  • Symptomatic postural hypotension,history or presence of drug or alcohol abuse, current smoker or previous smoker with a smoking history >10 pack-years.
  • Excessive consumption of beverages containing xanthine bases (more than 4 cups or glasses per day).

NOTE: Other Inclusion/Exclusion criteria may apply. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    SAR443765

    Single dose administration of SAR443765

    Drug: SAR443765 · Drug: Salbutamol or levosalbutamol

  • Placebo comparator
    Placebo

    Placebo to match SAR443765

    Drug: Placebo · Drug: Salbutamol or levosalbutamol

Interventions

  • solution for injection

  • DrugPlacebo

    solution for injection

  • DrugSalbutamol or levosalbutamol

    metered dose inhaler

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs) /TEAEs

    Incidence of adverse events (AEs) and treatment-emergent adverse events (TEAEs)

    Time frame: From baseline up to Day 71

Secondary outcomes

  1. Pharmacokinetic (PK) assessment: Cmax

    Observed maximum plasma concentration

    Time frame: From baseline up to Day 71

  2. Pharmacokinetic (PK) assessment: AUClast

    Area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to the real time tlast

    Time frame: From baseline up to Day 71

  3. Pharmacokinetic (PK) assessment: AUC

    Area under the serum concentration versus time curve extrapolated to infinity

    Time frame: From baseline up to Day 71

  4. Change in Nitric Oxide (FeNO) level

    Change from Baseline in FeNO level at Day 29

    Time frame: Day 1 and Day 29

  5. Presence of Anti-SAR443765 antibodies (ADA)

    Number of participant with SAR443765 antibodies

    Time frame: From baseline up to Day 71

  6. Total (free + bound) serum target concentrations of TSLP

    Change from baseline in total serum target concentrations of TSLP

    Time frame: From baseline up to Day 71

  7. Total (free + bound) serum target concentrations of IL-13

    Change from baseline in total serum target concentrations of IL-13

    Time frame: From baseline up to Day 71

07

Study locations

2 sites
  • Investigational Site Number : 2760001
    Berlin, Germany
  • Investigational Site Number : 8260001
    Belfast, BT9 6AD, United Kingdom
08

References and documents

Publications

  • Deiteren A, Krupka E, Bontinck L, Imberdis K, Conickx G, Bas S, Patel N, Staudinger HW, Suratt BT. A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule. Eur Respir J. 2025 Apr 24;65(4):2401461. doi: 10.1183/13993003.01461-2024. Print 2025 Apr. PubMed 39884759 ↗
  • Deiteren A, Bontinck L, Conickx G, Vigan M, Dervaux N, Gassiot M, Bas S, Suratt B, Staudinger H, Krupka E. A first-in-human, single and multiple dose study of lunsekimig, a novel anti-TSLP/anti-IL-13 NANOBODY(R) compound, in healthy volunteers. Clin Transl Sci. 2024 Jun;17(6):e13864. doi: 10.1111/cts.13864. PubMed 38924698 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Feb 2023, 8 months.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 8 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2022
First posted
May 9, 2022
StartActual
Jun 8, 2022
Primary completionActual
Feb 24, 2023
CompletionActual
Feb 24, 2023
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05366764
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 9, 2022
Start date
Jun 8, 2022
Primary completion
Feb 24, 2023
Completion
Feb 24, 2023
Last update
Sep 10, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lunsekimig

Start the discussion